Literature DB >> 22482279

Factors that affect acceptance of HIV microbicides among women.

Catherine A Domanska1, Anne M Teitelman.   

Abstract

Globally, women make up more than half of those infected with HIV. For women in nearly every region around the world, the primary mode of HIV transmission is through heterosexual sex. However, over thirty years into the HIV/AIDS epidemic women still lack sufficient means of protecting themselves against HIV. Vaginal HIV microbicides (VHMs) are a promising new method to prevent HIV infection. VHMs are chemical substances that can destroy HIV, block its entry into or fusion with the target cell or inhibit HIV replication once the virus has entered a target cell. They can be applied through various delivery methods intravaginally. VHMs are designed to be used by women and to that end it is crucial to understand women's preferences for formulation, use and other characteristics in order to determine how to increase adherence and acceptability. Of particular consideration is how relationship dynamics will affect microbicide usage. The purpose of this review is to examine the most recent body of literature regarding male and female perceptions of VHMs to prevent male to female transmission of HIV in order to gain a greater understanding of the factors that affect adherence and acceptability of VHM usage among women. A greater understanding of the factors that affect adherence and acceptance of VHMs will have an impact on the uptake of VHMs, allow nurses and other health care providers to counsel clients more effectively about their use and point to new directions needed on the research and development of future microbicides.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22482279     DOI: 10.1016/j.colegn.2011.09.006

Source DB:  PubMed          Journal:  Collegian        ISSN: 1322-7696            Impact factor:   2.573


  6 in total

1.  When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.

Authors:  Emily Namey; Kawango Agot; Khatija Ahmed; Jacob Odhiambo; Joseph Skhosana; Greg Guest; Amy Corneli
Journal:  Cult Health Sex       Date:  2016-04-19

2.  Personalized Biobehavioral HIV Prevention for Women and Adolescent Girls.

Authors:  Bridgette M Brawner; Anne M Teitelman; Amanda W Bevilacqua; Loretta Sweet Jemmott
Journal:  Glob Adv Health Med       Date:  2013-09

3.  An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana.

Authors:  Martha A Abdulai; Frank Baiden; George Adjei; Samuel Afari-Asiedu; Kwame Adjei; Charlotte Tawiah; Sam Newton
Journal:  BMC Womens Health       Date:  2012-11-01       Impact factor: 2.809

4.  Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa.

Authors:  Ariane van der Straten; Jonathan Stadler; Elizabeth Montgomery; Miriam Hartmann; Busiswe Magazi; Florence Mathebula; Katie Schwartz; Nicole Laborde; Lydia Soto-Torres
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

Review 5.  Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection.

Authors:  Christopher McConville; Peter Boyd; Ian Major
Journal:  Clin Med Insights Womens Health       Date:  2014-02-13

6.  Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.

Authors:  Kathleen M MacQueen; Sarah Dlamini; Brian Perry; Eunice Okumu; Steve Sortijas; Chitra Singh; Diantha Pillay; Alesha Majors; Sonja Jerome; Sharon Watson; Salim Abdool Karim; Quarraisha Abdool Karim; Leila E Mansoor
Journal:  AIDS Behav       Date:  2016-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.